Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies.
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population at a cost of over USD 1 billion per annum. Most hemodialysis grafts fail due to a venous stenosis (venous neointimal hyperplasia) which then results in thrombosis of the graft. Despite the magnitude of the clinical problem there are currently no effective therapies for this condition. The current review (a) describes the pathogenesis and pathology of venous stenosis in dialysis access grafts and (b) discusses the development and application of novel therapeutic interventions for this difficult clinical problem. Special emphasis is laid on the fact that PTFE dialysis access grafts could be the ideal clinical model for testing out novel local therapies to block neointimal hyperplasia.
Roy-Chaudhury
Prabir
P
University of Cincinatti Medical Center, Ohio 45267, USA. roychap@ucmail.uc.edu
Kelly
Burnett S
BS
Zhang
Jianhua
J
Narayana
Ashwath
A
Desai
Pankaj
P
Melham
Murad
M
Duncan
Heather
H
Heffelfinger
Sue C
SC
D000818:Animals; D002404:Catheterization / Q000009:adverse effects*; D002408:Catheters, Indwelling / Q000009:adverse effects; D003251:Constriction, Pathologic / Q000209:etiology / Q000473:pathology / Q000628:therapy; D006801:Humans; D006965:Hyperplasia / Q000209:etiology / Q000473:pathology / Q000628:therapy; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D006435:Renal Dialysis / Q000009:adverse effects* / Q000295:instrumentation